uk.finance.yahoo.com
Cure8 news brief
Why This Matters
This reports Phase 2b trial results for duvakitug showing improved remission and endoscopic response versus placebo in UC and CD—early evidence that could lead to a new treatment option if later trials confirm benefit and safety.
Who Should Pay Attention
Adults with moderate-to-severe UC or Crohn's disease, patients considering or on advanced therapies, clinicians treating IBD, and researchers tracking new drug development.
Study Snapshot
Story typeResearch news
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
New detailed Phase 2b results were presented for duvakitug (TEV'574/SAR447189) from the RELIEVE UCCD study in ulcerative colitis (UC) and Crohn's disease (CD). In UC, higher clinical remission rates at week 14 were reported for both 450 mg and 900 mg doses versus placebo, with larger placebo-adjusted effects at 900 mg.
In the CD cohort, endoscopic response at week 14 was higher with the 900 mg dose versus placebo; companies plan to start a Phase 3 program in H2 2025. The article summarizes efficacy outcomes (clinical remission in UC, endoscopic response in CD) and subgroup findings by prior advanced-therapy exposure.
It does not provide detailed safety data or full study methods in the extracted text; the original conference presentation would be the primary source for full results.
If you follow IBD clinical research, watch for the forthcoming Phase 3 program and peer-reviewed/full presentation materials for safety details, durability of response, and statistical context.
Keep In Mind
These are Phase 2b results presented at a conference; the article focuses on efficacy percentages but lacks full safety and methodological details. Phase 3 trials are planned, so this is promising early-stage data but not yet practice-changing.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationuk.finance.yahoo.com
Indexed viaBing News
Source typeResearch news
PublishedFeb 24, 2025, 5:22 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Phase 2b Results: Duvakitug Shows 48% Remission Rate in UC, Major Gains in Crohn's Disease
A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
Sanofi, Teva add to case for new bowel disease drug
The Phase 2b results suggest the investigational TL1A drug duvakitug improved clinical and endoscopic outcomes versus placebo in both ulcerative colitis and Crohn’s disease, which could expand future treatment options if...